Latest news with #Veracyte
Yahoo
6 hours ago
- Business
- Yahoo
VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up
Veracyte, Inc. VCYT delivered second-quarter 2025 adjusted earnings of 44 cents per share, which marked a stupendous improvement of 46.7% from the year-ago period's figure of 30 cents. The bottom line beat the Zacks Consensus Estimate by 41.9%. The company's GAAP loss per share (EPS) was 1 cent compared to the year-ago period's earnings of 7 cents per share. Following the earnings announcement, VCYT's share price gained 15.5% last Thursday. VCYT's Q2 Revenues Revenues increased 13.8% year over year to $130.2 million, which outpaced the Zacks Consensus Estimate by 7.1%. VCYT's Q2 Segmental Details Testing revenues totaled $122.3 million, up 14% year over year. This rise was mainly due to Decipher and Afirma revenue growth of 24% and 5%, respectively. Testing volume improved 18% year over year to 42,441 tests. Product revenues fell 8% year over year to $3.6 million. Biopharmaceutical and other revenues of $4.3 million reflected a 21% increase from the prior-year quarter's figure. Margins The total cost of revenues (product, testing, biopharmaceutical and other) was $37.7 million, up 12.3% year over year. The gross profit rose 14.4% to $92.4 million. The gross margin expanded 38 basis points (bps) to 71%. Selling and marketing expenses rose 4.5% to $25.3 million, while general and administrative expenses increased 1.8% to $32.3 million. R&D expenses totaled $16.3 million, down 1.2% year over year. The adjusted operating margin was 14.2%, which expanded 689 bps year over year. VCYT's Cash, Capital Structure and Solvency Veracyte exited second-quarter 2025 with cash and cash equivalents of $219.5 million compared with $186.1 million at the end of the first quarter. The cumulative net cash provided from operating activities at the end of the reported quarter was $39 million compared with $20.6 million a year ago. VCYT's 2025 Guidance Veracyte raised its full-year 2025 testing revenue guidance. The company expects testing revenues to be in the range of $477-$483 million (up from $470-$480 million), implying 14% to 15% year-over-year growth. Veracyte, Inc. Price, Consensus and EPS Surprise Veracyte, Inc. price-consensus-eps-surprise-chart | Veracyte, Inc. Quote Given the resolution of the French subsidiary proceedings, the company initiated full-year 2025 total revenue guidance of $496-$504 million, implying 11% to 13% year-over-year growth. The Zacks Consensus Estimate for the metric is currently pegged at $501.1 billion. The company raised guidance for adjusted EBITDA as a percentage of revenues. It is anticipated to be approximately 23.5% (up from the previous guidance of 22.5%). Our Take Veracyte reported better-than-expected second-quarter results, with its earnings and revenues surpassing their respective estimates. The company registered robust growth from its market-leading Decipher Prostate and Afirma tests. Meanwhile, the growth in Biopharmaceutical and other revenues was encouraging. Both margin expansion instills optimism among investors. In the second quarter, the company had some notable developments, including the launch of Decipher Prostate Metastatic Genomic Classifier for use in patients whose prostate cancer has spread beyond the primary tumor. Zacks Rank and Key Picks Veracyte currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Medpace Holdings MEDP, GeneDx Holdings WGS and Cardinal Health CAH. Medpace Holdings, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2025 EPS of $3.1, which beat the Zacks Consensus Estimate by 3.33%. Revenues of $603.3 million topped the consensus mark by 11.48%. You can see the complete list of today's Zacks #1 Rank stocks here. MEDP has a historical five-year earnings growth rate of 30.9% compared with the S&P 500 composite's 10.1% growth. GeneDx Holdings, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter 2025 adjusted EPS of 50 cents, which exceeded the Zacks Consensus Estimate by a remarkable 400%. Revenues of $102.7 million surpassed the Zacks Consensus Estimate by 21.24%. WGS has an estimated earnings growth rate of 79.6% for 2026 compared with the industry's 18.6% growth. Cardinal Health, carrying a Zacks Rank #2 at present, posted third-quarter fiscal 2025 adjusted EPS of $2.35, which exceeded the Zacks Consensus Estimate by 9.3%. Revenues of $54.88 billion missed the Zacks Consensus Estimate by 0.3%. CAH has an estimated long-term earnings growth rate of 10.9% compared with the industry's 9.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Veracyte, Inc. (VCYT) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report GeneDx Holdings Corp. (WGS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
4 days ago
- Business
- Business Insider
Veracyte price target lowered to $28 from $29 at Morgan Stanley
Morgan Stanley analyst Tejas Savant lowered the firm's price target on Veracyte (VCYT) to $28 from $29 and keeps an Underweight rating on the shares. The company reported a solid Q2 beat on continued Decipher/Afirma momentum leading to a 2025 guidance raise, the analyst tells investors in a research note. The firm added that Veracyte's pipeline is promising an represents substantial opportunity, though meaningful upside remains a 2027+ dynamic. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yahoo
26-07-2025
- Business
- Yahoo
Veracyte (VCYT) Soars 7% on S&P SmallCap 600 Inclusion
We recently published . Veracyte, Inc. (NASDAQ:VCYT) is one of the best-performing stocks on Friday. Veracyte grew its share price by 7.04 percent on Friday to close at $25.25 apiece following announcements that it was set to join the S&P SmallCap 600 beginning on Tuesday, July 29. This followed the removal of the Triumph Group following its planned merger with Warburg Pincus LLC and Berkshire Partners LLC. Companies joining market indices typically see their share prices rise as investment firms begin adding them to the portfolios tracking the said indices. Additionally, index memberships bolster a stock's visibility among institutional and retail investors. In other news, Veracyte, Inc. (NASDAQ:VCYT) said that it will announce the results of its financial and operating highlights for the second quarter of the year after market close on August 6. A conference call will be held at 4:30 PM to discuss more details about the performance. Photo by National Cancer Institute on Unsplash Veracyte, Inc. (NASDAQ:VCYT) is a global diagnostics company seeking to advance and transform cancer care for patients all over the world. While we acknowledge the potential of VCYT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
Business Insider
25-07-2025
- Business
- Business Insider
Veracyte to replace Triumph Group in S&P 600 at open on 7/29
Veracyte (VCYT) will replace Triumph Group (TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. Warburg Pincus and Berkshire Partners will acquire Triumph Group in a deal expected to close soon, pending final closing condition. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yahoo
17-07-2025
- Business
- Yahoo
Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025
SOUTH SAN FRANCISCO, Calif., July 17, 2025--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter of 2025 after the close of market on Wednesday, August 6, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at The conference call dial-ins can be accessed by registering via this link. About Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit or follow us on LinkedIn or X (Twitter). View source version on Contacts Investors Shayla Gormaninvestors@ (619) 393-1545 Media Tracy Morrismedia@ (650) 380-4413 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
